Symbol="CLLS"
AssetType="Common Stock"
Name="Cellectis SA"
Description="Cellectis SA, a clinical-stage biotechnology company, develops immuno-oncology products based on gene-edited T cells that express chimeric antigen receptors to attack and eradicate cancer cells. The company is headquartered in Paris, France."
CIK="1627281"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)"
Address="8 RUE DE LA CROIX JARRY, PARIS, LLE-DE-FRANCE, FR"
FiscalYearEnd="December"
LatestQuarter="2023-03-31"
MarketCapitalization="116170000"
EBITDA="-73291000"
PERatio="None"
PEGRatio="0"
BookValue="2.046"
DividendPerShare="0"
DividendYield="0"
EPS="-2.04"
RevenuePerShareTTM="0.542"
ProfitMargin="0"
OperatingMarginTTM="-3.272"
ReturnOnAssetsTTM="-0.174"
ReturnOnEquityTTM="-0.607"
RevenueTTM="25483000"
GrossProfitTTM="23952000"
DilutedEPSTTM="-2.04"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="-0.063"
AnalystTargetPrice="7.8"
TrailingPE="-"
ForwardPE="-"
PriceToSalesRatioTTM="4.479"
PriceToBookRatio="0.75"
EVToRevenue="5.07"
EVToEBITDA="-0.64"
Beta="2.001"
num_52WeekHigh="4.1"
num_52WeekLow="1.68"
num_50DayMovingAverage="1.9"
num_200DayMovingAverage="2.237"
SharesOutstanding="55584000"
DividendDate="None"
ExDividendDate="None"
symbol="CLLS"
open="2.05"
high="2.14"
low="2.02"
price="2.12"
volume="39190.00"
latest_trading_day="2023-07-10"
previous_close="2.01"
change="0.11"
change_percent="5.4412%"
aroon_positive_momentum_days="44"
aroon_negative_momentum_days="0"
trend_strength="Absent or Weak Trend"
buying_signal="Weak Buy Signal"
volume_analysis="Target Volume"
value_analysis="Expected Range"
Aroon_change="FALSE"
Aroon_momentum="44"
Volume_recent_avg="59643"
Change_recent_avg="-0.01"
Delta_recent_avg="0.1"
Variance_recent_avg="0.05"
Change_ratio_recent_avg="-0.3"
RSI_change="FALSE"
ADX_change="FALSE"

event="FALSE"
Aroon_signal="positive"
Aroon_change="FALSE"
Aroon_momentum_positive="44"
Aroon_momentum_negative="56"
image_negative_thumbnail_id_1="1165"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0199.jpeg"
image_negative_thumbnail_id_2="497"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0108.jpeg"
image_neutral_thumbnail_id_1="575"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0024.jpeg"
image_neutral_thumbnail_id_2="529"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0070.jpeg"
image_positive_thumbnail_id_1="983"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0145.jpeg"
image_positive_thumbnail_id_2="601"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0107.jpeg"
image_professor_thumbnail_id_1="1174"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0008.jpeg"
image_professor_thumbnail_id_2="1189"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0023.jpeg"
